| Tbio | Mitochondrial amidoxime-reducing component 1 |
As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively.
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Amphetamine-Related Disorders | 74 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 4.5e-38 |
| tuberculosis | 2010 | 1.2e-07 |
| ovarian cancer | 8520 | 5.4e-07 |
| medulloblastoma, large-cell | 6241 | 3.0e-05 |
| group 3 medulloblastoma | 4104 | 1.4e-04 |
| ductal carcinoma in situ | 1745 | 2.7e-04 |
| osteosarcoma | 7950 | 3.7e-04 |
| interstitial cystitis | 2312 | 2.9e-03 |
| invasive ductal carcinoma | 2951 | 3.0e-03 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Hemolytic anemia | 77 | 0.0 | 1.4 |
| Myocardial Infarction | 151 | 0.0 | 2.2 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Tetralogy of Fallot | 63 | 3.253 | 1.6 |
| Disease | log2 FC | p |
|---|---|---|
| ductal carcinoma in situ | -2.500 | 2.7e-04 |
| group 3 medulloblastoma | 1.200 | 1.4e-04 |
| interstitial cystitis | -1.100 | 2.9e-03 |
| invasive ductal carcinoma | -2.500 | 3.0e-03 |
| medulloblastoma, large-cell | 1.100 | 3.0e-05 |
| osteosarcoma | -2.464 | 3.7e-04 |
| ovarian cancer | 1.200 | 5.4e-07 |
| psoriasis | -1.400 | 4.5e-38 |
| tuberculosis | 2.300 | 1.2e-07 |
MGAAGSSALARFVLLAQSRPGWLGVAALGLTAVALGAVAWRRAWPTRRRRLLQQVGTVAQLWIYPVKSCK 1 - 70 GVPVSEAECTAMGLRSGNLRDRFWLVINQEGNMVTARQEPRLVLISLTCDGDTLTLSAAYTKDLLLPIKT 71 - 140 PTTNAVHKCRVHGLEIEGRDCGEATAQWITSFLKSQPYRLVHFEPHMRPRRPHQIADLFRPKDQIAYSDT 141 - 210 SPFLILSEASLADLNSRLEKKVKATNFRPNIVISGCDVYAEDSWDELLIGDVELKRVMACSRCILTTVDP 211 - 280 DTGVMSRKEPLETLKSYRQCDPSERKLYGKSPLFGQYFVLENPGTIKVGDPVYLLGQ 281 - 337 //
